HR-6314-119
Referred to the Subcommittee on Health.
Sponsored by Ritchie Torres (D-NY)
What it does
The Lung Cancer Screening Expansion Act of 2025 would broaden access to lung cancer screening — most likely low-dose computed tomography (LDCT) scans — by expanding coverage requirements under federal health programs such as Medicare, or by modifying eligibility criteria for who qualifies for covered screenings. Because the bill text provided is limited to its title and referral status, the precise mechanical changes (e.g., age thresholds, smoking history requirements, or insurer mandates) are not available for detailed analysis.
Who benefits
Current and former smokers who do not meet existing eligibility criteria for covered LDCT screenings. Older adults and those with lower incomes who rely on Medicare or Medicaid. Patients in rural or underserved areas with limited access to preventive care. Radiologists, imaging centers, and pulmonologists who would see increased demand for screening services. Oncology providers who may treat cancers caught at earlier, more treatable stages.
Who is hurt
Federal and state governments that would bear increased program costs. Private insurers and employer-sponsored health plans that may face new coverage mandates, potentially passing costs to policyholders through higher premiums. Taxpayers who fund Medicare and Medicaid. Competing preventive care programs that may face resource trade-offs if funding is redirected.
Supporters argue
Supporters argue that lung cancer is the leading cause of cancer death in the United States, killing more than 125,000 Americans annually, and that LDCT screening has been shown to reduce lung cancer mortality by up to 20% in high-risk populations, per the National Lung Screening Trial. They contend that current Medicare eligibility criteria — which require a specific age range and heavy smoking history — leave many at-risk individuals without covered access, and that expanding screening would catch more cancers at earlier, less costly, and more survivable stages.
Opponents argue
Opponents argue that broadening screening eligibility could expose lower-risk individuals to unnecessary radiation, false positives, and invasive follow-up procedures, citing U.S. Preventive Services Task Force data showing that LDCT screening produces false-positive rates exceeding 95% in some populations. They contend that expanding federal coverage mandates increases program costs without a demonstrated net benefit for newly eligible groups, and that coverage decisions are better made by independent medical advisory bodies rather than through legislation that may not keep pace with evolving clinical evidence.